Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Rosiglitazone (Brl-49653): Applied Protocols in Metabolic Re
2026-04-21
Rosiglitazone (Brl-49653) empowers metabolic research with reproducible PPARγ activation, facilitating advanced studies in adipogenesis, insulin sensitivity, and rare disease rescue. This article translates cutting-edge findings—such as SEMA3E-driven beige adipocyte differentiation—into actionable protocols, troubleshooting guides, and workflow optimizations for experimental success.
-
Paclitaxel (Taxol): Cytoskeletal Regulation Beyond Cancer Re
2026-04-21
Explore how Paclitaxel (Taxol) enables advanced insights into cytoskeletal dynamics, bridging recent discoveries in tubulin post-translational modifications with next-generation cancer research. Unique practical guidance for protocol design and mechanistic studies.
-
Fosinopril Sodium: Precision ACE Inhibition for Translationa
2026-04-20
Explore how Fosinopril sodium, a potent ACE inhibitor, enables advanced translational research in hypertension and cardiovascular disease. This article offers a mechanistic deep-dive, unique protocol guidance, and actionable insights for assay design.
-
PERK Loss Sensitizes Colorectal Cancer to Ferroptosis via SL
2026-04-20
The referenced study demonstrates that loss of PERK function promotes ferroptosis in colorectal cancer by downregulating SLC7A11, a key regulator of cystine import and glutathione synthesis. These findings suggest that targeting the PERK arm of the unfolded protein response could enhance vulnerability of therapy-resistant tumors to ferroptosis, informing new strategies for cancer treatment.
-
Chlorpromazine HCl: Dopamine Receptor Antagonist for Researc
2026-04-19
Chlorpromazine HCl is a well-characterized dopamine receptor antagonist with broad utility in neuropharmacology and psychotic disorder research. Its mechanism involves potent dopamine receptor inhibition, GABAA receptor modulation, and emerging roles in host-pathogen interaction studies. This dossier details its validated applications, protocol parameters, and limitations with direct evidence links.
-
Systematic Evaluation of AKT Inhibitors: Mechanisms and Impl
2026-04-18
Kostaras et al. performed a systematic molecular and pharmacologic evaluation of ATP-competitive and allosteric AKT inhibitors, revealing marked drug- and class-specific differences in biological activity. Their work highlights the importance of structural and functional profiling for optimizing the use of AKT inhibitors in cancer research and therapeutic development.
-
Aspirin's Role in Limiting Cancer Metastasis via Platelet-T
2026-04-17
This study reveals that aspirin impedes cancer metastasis by disrupting platelet-derived thromboxane A2 (TXA2)-mediated suppression of T cell immunity. The findings clarify the immune mechanisms underlying aspirin’s anti-metastatic effect and delineate a novel TXA2–ARHGEF1 pathway as a target for future immunotherapies.
-
PP 2 (AG 1879): Precision Src Inhibition in Cell Signaling S
2026-04-16
PP 2 (AG 1879) empowers researchers to dissect Src-mediated pathways with high selectivity and reproducible potency, making it a gold-standard tool in cancer biology, immunology, and cytoskeletal signaling research. Explore optimized protocols, advanced troubleshooting, and unique insights from recent studies to maximize experimental reliability.
-
Tobramycin: Applied Protocols for Gram-Negative Bacteria Res
2026-04-15
Tobramycin, a water-soluble aminoglycoside antibiotic from APExBIO, enables reproducible microbiology workflows targeting Gram-negative bacterial infections. This guide details optimized protocols, troubleshooting strategies, and actionable insights that translate bench evidence into robust experimental outcomes.
-
Serotonin Inhibits HRP-Mediated Biotinylation: Mechanism and
2026-04-14
This study identifies serotonin as a specific inhibitor of HRP-mediated proximity-dependent biotinylation, a key method for mapping subsynaptic proteomes in neuroscience. The authors introduce an azocoupling strategy to restore labeling efficiency, informing future protein profiling in serotonergic systems.
-
V5 Epitope Tag Peptide: Atomic Evidence for Protein Tagging
2026-04-13
The V5 Epitope Tag Peptide (GKPIPNPLLGLDST) is a validated, high-purity synthetic tag for recombinant protein detection and purification. Its utility is supported by peer-reviewed antibody screening and robust solubility data, making it a reliable choice for Western blotting and immunoprecipitation workflows.
-
Trametinib (GSK1120212): Reliable MEK Inhibitor for Reproduc
2026-04-12
Discover how Trametinib (GSK1120212) (SKU A3018) addresses core challenges in cell viability, proliferation, and cytotoxicity assays. This scenario-driven guide delivers practical, literature-backed solutions for reliable MEK-ERK pathway modulation, underlining Trametinib's robust performance, reproducibility, and workflow compatibility in oncology research.
-
ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR
2026-04-12
This study introduces a combinatorial library of biodegradable lipid nanoparticles with ROS-sensitive thioketal moieties that enable selective mRNA delivery to tumor cells. The findings highlight enhanced gene expression and antitumor efficacy, advancing targeted mRNA therapeutics.
-
Z-YVAD-FMK: Precision Caspase-1 Inhibitor for Pyroptosis Res
2026-04-11
Z-YVAD-FMK enables selective caspase-1 inhibition for dissecting inflammasome pathways, apoptosis, and pyroptosis in advanced cellular models. Its irreversible and cell-permeable action, supported by robust application data, streamlines workflows and enhances reproducibility in cancer and inflammation research.
-
Deferasirox: Oral Iron Chelator Workflows for Cancer & Overl
2026-04-11
Deferasirox stands out as a powerful oral iron chelator, enabling both iron overload management and advanced cancer research via iron metabolism targeting. This guide delivers actionable workflows, troubleshooting strategies, and data-driven insights to maximize reproducibility and translational impact.